November 7, 2018
JUPITER, FL / ACCESSWIRE / November 7, 2018 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at fl...
November 5, 2018
Data Demonstrate C1 Can Be Developed Into a New-Generation Therapeutic Protein Production System
November 5, 2018
JUPITER, FL / ACCESSWIRE / November 5, 2018 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible ...
October 24, 2018
JUPITER, FL / ACCESSWIRE / October 24, 2018 / Dyadic International, Inc. (''Dyadic'') (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexibl...
October 16, 2018
JUPITER, Fla., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and dru...
October 1, 2018
JUPITER, FL / ACCESSWIRE / October 1, 2018 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at flex...
September 17, 2018
NEW YORK, NY / ACCESSWIRE / September 17, 2018 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and drugs at ...
September 7, 2018
JUPITER, Fla., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and dr...
August 9, 2018
JUPITER, Fla., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and lower the cost of biologic vaccines and dru...
July 26, 2018
JUPITER, Fla., July 26, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at f...